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ABSTRACT 
Objective: The objective of this selective EBM review is to determine whether or not oral 
dextromethorphan provides pain relief in patients with diabetic neuropathy. 
 
Study Design: Review of three peer-reviewed, double blind, randomized control trials published 
between 1995-2012.   
 
Data Sources: Studies were selected through Cochrane Library Collection and PubMed and 
chosen based on their relevance to the clinical question as well as their inclusion criteria; 
including adults over the age of 18; and those who were experiencing daily pain of moderate 
intensity, for at least half of the day, over a span of 3 months. 
 
Outcomes Measured:  Each RCT measured the same outcome but in a different way.  In the 
Nelson study, pain relief was measured using a13-word descriptor scale; for the Sani study, pain 
relief was measured using a category rating scale; and the Shaibani trial measured pain relief 
using a Pain Relief Rating scale. 
 
Results:  It was assessed and recorded in all three RTCs that the efficacy of oral 
dextromethorphan in pain relief was statistically significant when compared to a placebo. 
 
Conclusions:  Oral dextromethorphan has been shown to give pain relief to patients with diabetic 
neuropathy.  With further research using larger sample sizes and assessment of long-term 
adverse reactions, dextromethorphan may be made a common treatment for diabetic neuropathy. 
 
Key Words: dextromethorphan, diabetic neuropathy, peripheral neuropathy 
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INTRODUCTION 
Diabetic neuropathy (DN) is a common complication of diabetes, where damage to 
nerves leads to mild/severe disabling pain.  It is hypothesized and suggested that diabetic 
neuropathy is caused by an abnormal hyper excitability induced by excitatory neurotransmitters 
(NT) such as glutamate and aspartate, which are dependent on activation of NMDA receptors1.  
Therefore, current treatments have been based around drugs that block or inhibit NMDA 
receptors1. 
 In the United States, ~25.8 million people are affected by diabetes (DM).  Of that 25.8 
million, ~25.6 million are over the age of 202. Between 60-70% of people with DM experience 
some form of nerve damage, known as diabetic neuropathy.  DN and its complications cost the 
US between $4.6-$13.7 billion annually; most of these costs are attributed to Type 2 diabetics3.  
There is not an exact estimate of how many health care visits result in caring for patients 
suffering from diabetic neuropathy specifically; however, in 2008, 44,021 DM type 2 patients 
were identified of getting a minimum of 12 months of continuous follow-up care and 32, 991 
DM type 2 patients were found to have ~24 months of continuous health-plan enrollment4.  The 
majority of these patients had at least one physician office visit (99.8%), laboratory diagnostic 
test (96.2%), and other outpatient visits (97.5%)4.  Although the exact number of health care 
visits for diabetic neuropathy is unknown, the costs are exponentially high. 
Diabetic neuropathy is triggered by multiple factors.  The six main factors that can 
contribute to DN include: metabolic (ex. high blood glucose or long term diabetes); 
neurovascular (ex. damage to blood vessels that carry oxygen/nutrients); autoimmune (ex. 
inflammation to nerves); mechanical injury (ex. carpel tunnel); inherited traits (ex. nerve 
disease); or lifestyle factors (ex. smoking or drinking) 5.  Just like the causes of diabetic 
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neurothapy are many, the types of diabetic neuropathy are numerous, as well. Diabetic 
neuropathy can be broken down into four distinct classifications.  These classifications include 
peripheral, autonomic, proximal, and focal5.  The most common subtype that people experience 
is peripheral neuropathy.  Peripheral neuropathy is characterized by pain or numbness felt in the 
toes, feet, legs, hands, and/or arms5. Autonomic neuropathy causes alterations in organ functions 
such as digestion, sexual response, perspiration, and bowel and bladder function5. Proximal 
neuropathy, or the opposite of peripheral neuropathy, causes pain in the buttocks, thighs, and/or 
hips5.  This pain eventually causes weakness in the legs5.  Finally, focal neuropathy results in a 
sudden onset of pain in a specific nerve or nerve group5.  These weak nerves lead to muscle 
weakness and/or pain.  In focal neuropathy, any nerve/nerve group can be affected5. The multiple 
causes and forms of diabetic neuropathy highlights why this medical condition is interfering with 
and affecting so many diabetics’ lives.  Furthermore, this noted information explains why so 
many healthcare hours and dollars are spent, each year, towards this medical complication. 
Currently diabetic neuropathy is managed multiple ways.  The first step to take in the 
control of DN is managing blood sugar levels.  Managing and controlling blood sugar levels 
helps prevent further nerve damage5. The next phase in regulating DN is controlling the pain 
associated with the nerve damage.  Presently, a variety of medications are being used to alleviate 
the patient’s discomfort. Common drugs used to treat the pain include tricyclic antidepressants 
(ex: amitriptyline); antidepressants which include duloxetine, venlafaxine, bupropion, 
paroxetine, and citalopram; anticonvulsants such as pregabalin or gabapentin; and opioids or 
opioid-like drugs, including oxycodone or tramadol5.   An alternative pain reliever for those 
experiencing diabetic neuropathy is dextromethorphan, an NMDA receptor antagonist.  Although 
multiple medications are available to help reduce nerve damage and pain, these treatments are 
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not managing everyone.  Many people are still struggling and suffering from diabetic neuropathy 
and its complications. 
OBJECTIVE 
 The objective of this systematic review is to determine whether or not oral 
dextromethorphan provides pain relief in patients with diabetic neuropathy. 
METHODS 
 This review is comprised of three randomized controlled, double blind, clinical trials that 
meet specific criteria for the comparison of dextromethorphan for pain relief in patients with 
diabetic neuropathy.  The first trial was a RCT double blind study comparing pain relief between 
dextromethorphan and a placebo.  The second RCT double blind study examined the efficacy of 
dextromethorphan and an active placebo.  The third RCT double blind study assessed 3 different 
study groups.  Two groups received a drug combination, while the third group received a 
placebo.  The two combo drugs used were dextromethorphan30/quinidine 30 (DMQ 30/30mg) 
and DMQ 45/30mg.  The only difference between these groups was the strength of 
dextromethorphan. The populations within all of these trials consisted of adults older than 18 
who had daily pain of at least moderate intensity, for at least 50% of the day, for a period of 3 
months.  The populations excluded from these studies were patients younger than 18 years old 
and patients who were experiencing any other type of pain not related to their diabetic 
neuropathy. 
 Key words used in the research for these studies were dextromethorphan, diabetic 
neuropathy, and peripheral neuropathy.  All articles used in this research were peer-reviewed 
journals and were investigated via key words on Cochrane Library Collection and PubMed.  
Selection of the articles researched had to meet several inclusion criteria: material contained in 
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the article had to be relevant to the proposed clinical question, the article’s publishing dates had 
to be from 1996 to present date, and the articles had to be presented as a patient oriented 
outcome study.  Exclusion criteria included articles published prior to 1996, articles that focused 
on disease oriented outcomes versus patient oriented outcomes, or articles that included 
participants suffering from any other type of pain.  Statistics used within two of these studies 
included: control event rate (CER), experimental event rate (EER), number needed to treat 
(NNT), confidence interval (CI), relative benefit increase (RBI), absolute benefit increase (ABI), 
and p-value.  The other study used p-value, confidence interval, and paired t-test.  Below, Table 
1 displays the demographics and characteristics of the studies reviewed and used. 
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Table 1: Demographics and Characteristics of included studies 
Study Type #Pts Age 
(yrs) 
Inclusion 
Criteria 
Exclusion 
Criteria 
W/D Interventions 
Nelson6 
(1997) 
Double 
blind 
RCT 
32 18-
85 
y/o 
-Complete pain 
diary 
-Diagnosis of 
diabetes 
-Distal, 
symmetrical 
DN 
 -Presence 
of any other 
pain 
condition 
-Unstable 
disease 
process  
-Liver or 
kidney 
disease 
-Concurrent 
use of 
MAOIs 
6 Two six-week drug 
treatment periods (one 
with the active drug and 
one with the placebo), 
separated and completed 
by a week washout 
period. 
Sang7 
(2002) 
Double 
blind 
RCT 
55 ≥18 
y/o 
-Experiencing 
moderate pain 
daily for over a 
minimum of 3 
month span 
due to DN 
-Previously 
failed trial of 
TCAs for at 
least 2 weeks 
or development 
of side effects 
-Glucose 
control 
-Stable 
analgesic 
regimen for 2 
weeks 
- suffering 
from any 
other type 
of pain 
-Liver, 
cardiac or 
kidney 
disease 
-S&Sx of 
any central 
neurologic 
disorder 
-Concurrent 
use of 
MAOI 
9 Two randomized placebo 
controlled, double blind 
trials took place during 
this study.  The first study 
was an “efficacy trial” 
where the effects of 
dextromethorphan, 
memantine, and the active 
placebo (lorazepam) were 
compared.  The second 
study was a “dose-
response” trial of 
preferred active drug in 
participants.  Their pain 
and side effects levels 
were assessed 2x/week. 
Shaibani1 
(2012) 
Double 
blind 
RCT 
379 ≥18 
y/o 
-Diagnosed 
with diabetes 
type 1 or 2  
-Documented 
glucose control 
-Experiencing 
painful diabetic 
distal sym. 
sensory/motor 
polyneuropathy 
for at least the 
3 months prior 
-Failing ≥3 
pain 
medications 
-Require 
narcotics 
for pain 
control 
-Sensitivity 
to quinidine 
or opiates 
-Prior tx 
with DMQ 
137 All patients were 
randomly divided into 
one of three groups 
Dextormehorphan/quinine 
(DMQ) 45/30mg, DMQ 
30/30mg, and a placebo 
group.  Over a 13 week 
period pain relief was 
assessed with 4 different 
mechanisms. 
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OUTCOME MEASURED 
 
 Although each study had their own method of measurement, the outcome measured was 
the same.  This outcome was pain relief.  In the Nelson study, pain relief descriptors were 
compared with the placebos using a Mann-Whitney U test.  The primary outcome variable was 
the participants’ mean pain rating during the last 7 days of the group taking dextromethorphan 
compared with the last seven days of the trial group taking the placebo. Outcome was calculated 
using a paired t-test.  The second trial, Sani study, used a category rating scale to measure pain 
relief.  Finally, the Shaibani study used a 5-point Pain Intensity Rating Scale, which assessed 
baseline pain and pain on days 15, 29, 50, 71, and 92 during a clinical visit.   
RESULTS 
In all three RCT double blind studies, the efficacy of dextromethorphan is compared with 
a placebo or both a placebo and an alternative medication.  In the Nelson study, a total of 14 
patients entered the study, of which 13 completed both treatments.  The patients in this study, 
first started with a one-week baseline period, followed by two six-week treatment periods, which 
was separated by a one-week “washout” period6.  When given the dextromethorphan, the 
patients first started with 120mg QID and titrated to a maximum of 960mg daily.  While one 
group was randomly given dextromethorphan, the other was receiving the lactose placebo6.  
Every 3 days, a nurse contacted the participants to titrate medication dosage and to assess pain, 
adverse reactions, and compliance6.  Every three days the patients increased their medication by 
30-60mg/day unless adverse reactions began affecting daily activities, the patient reported 
complete pain relief, or if the maximum dose was reached6.  During the last two weeks, week 5 
and 6, the highest well-tolerated dose was kept at a constant level6.  
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 During the last week of the study, dextromethorphan reduced pain by a mean of 24% 
compared to that of the placebo6.  Scores were determined by measuring pain relief on a 13-word 
descriptor scale.  The results showed that while on dextromethorphan, pain was relieved: “a lot, 
4; moderate, 3; slight, 4; none, 2; and pain worse, 0;” versus the “placebo: a lot, 0; moderate, 0; 
slight, 6; none, 5; and pain worse, 26.  No participant admitted to full pain relief with either 
treatment period6.  The means of the global scores were: dextromethorphan: 2.7 and placebo 
1.36.  Those who reported moderate or better pain relief with dextromethorphan described their 
lowest pain experience while on the highest dextromethorphan dose tolerated6.  As shown in 
Table 2, when measuring pain relief, researchers calculated a p-value of 0.01, indicating that this 
study was statistically significant. 
Table 2: Nelson Study: Dextromethorphan vs. Placebo6 
Outcome measured p-value Confidence Interval (CI) 
Pain relief 0.01 95% 
 
In the Sang Study, 23 participants were selected for the study, 19 of who completed the 
study in its entirety7.  In this RCT double blind trial, the patients participated in two different 
trials.  The first was an efficacy trial, which consisted of a three period, three treatment balanced 
Latin square design which assessed the relationship between the maximally tolerated doses 
(MTD) of dextromethorphan (MTD=960mg), memantine, and an active placebo (lorazepam)7.  
The second study was a dose-response trial, which consisted of a four period, four treatment 
Latin square design in “responders” comparing the pain relief recorded at different stages of 
treatment dosing (0, 25, 50, 100%) up to the maximal tolerated dose determined in the first trial, 
versus the active placebo7.  During the trials, all medications were dispensed in identical 
appearing capsules7.  Each treatment period consisted of a one-week baseline period followed by 
a seven-week period where the medications were given 4 times throughout the day7.  A nurse, 
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also blinded to the study drug, contacted the patient approximately twice weekly to assess the 
adverse reactions and to titrate the medication.  After the 7 weeks, the patients completed a 2-
week washout period before beginning the next trial7.  At the end of the efficacy trial, pain relief 
was measured using a category rating scale7.  When comparing the efficacy between 
dextromethorphan and the active placebo; 13 of 19 patients reported moderate or better pain 
relief with dextromethorphan compared to the 7 of 19 who reported moderate to better pain relief 
with the placebo7.  The findings at the conclusion of the dose-response trial were: zero patients 
reported moderate or better pain relief with placebo (0% MTD), one patient reported pain relief 
with 25% MTD, six with 50% MTD, and ten with 100% MTD7.  Although researchers found 
that 25% MTD of dextromethorphan was not statistically better than lorazepam, it was concluded 
that both 50% and 100% MTD of dextromethorphan was statistically better than the placebo7.  
Below, Table 3 compiles a summary of the Sang study’s findings.  Using the control event rate 
and the experimental event rate, the relative benefit increase was calculated as 84% and the 
absolute benefit increase was found to be 31%.  Using the ABI, numbers needed to treat was also 
calculated.  Numbers needed to treat for this study was 4.  This means that for every 4 people 
treated with dextromethorphan, one more had pain relief compared to the control group.  
Table 3: Sang Study: Dextromethorphan vs. Active placebo (lorazepam)7 
CER 
Placebo 
Lorazepam 
EER 
Oral 
Dextromethorphan 
RBI ABI NNT p-value 
0.37 0.68 0.84 0.31 4 0.12 
 
In the Shaibani Study, 131 participants were randomized into the Dextromethorphan 
45/quinidine 30mg (DMQ 45/30) group and 123 were randomized into the placebo group1. In the 
DMQ 45/30mg group, 131 participants started, but only 79 completed the study1.  Of the 123 
who were in the placebo group, only 89 completed the trial1.  Throughout the study, all of the 
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participants completed a 13-week, phase 3 RCT where four pain rating scales were applied daily 
using diaries and five-clinic visits1.  On days 1, 15, 29, 50, 71, and 92, a 6-point categorical Pain 
Relief Rating Scale was used to record and classify the relief of their leg pain, compared with 
baseline1.  The primary analysis assessed the profile of daily Pain Rating Scale scores of the 
experimental group compared to those of the control group using a mixed-effects regression 
model1.  Researchers found that in both the overall profile and on days 30, 60, 90, the DMQ 
45/30mg was statistically significant in pain relief when compared to the placebo1.   Researchers 
also saw a 30% Pain Rating Scale score reduction for 83% of the patients on DMQ 45/30mg 
compared to a reduction in only 61% of the patients on the placebo1.  Finally, 66% of 
participants taking DMQ 45/30mg compared to 39% of the placebo group achieved a 50% 
reduction on the pain scoring scale1.  Table 4, summarizes the results calculated and recorded for 
the Shaibani study.  Once again, using the control event rate and the experimental event rate, the 
RBI and ABI were calculated.  In this study the relative benefit was calculated as 39% and the 
absolute benefit increase was recorded as 66%. Numbers needed to treat for this study was also 
4.   
Table 4: Shaibani Study: DMQ 45/30mg vs. Placebo1 
CER 
Placebo 
EER 
DMQ 
45/30mg 
RBI ABI NNT p-value 
0.39 0.66 0.69 0.27 4 0.001 
 
DISCUSSION 
 This systematic review assessed the use of dextromethorphan for pain relief in patients 
with diabetic neuropathy.  Although dextromethorphan is FDA approved as a cough suppressant, 
due to its mechanism of action, it has been found to help relieve neuropathy as well.  
Dextromethorphan is an attractive medication because it is a low affinity, non-competitive, 
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channel blocking NMDA receptor antagonist6.  It is hypothesized that by blocking these 
receptors, it would inhibit the abnormal CNS excitation seen in diabetics and potentially alleviate 
their experienced pain6.   Even though each study reviewed was structured differently, the final 
results were similar.  As hypothesized, dextromethorphan proved to relieve pain better than its 
competing placebo. Therefore, these studies give physicians and patients another treatment 
option for diabetic neuropathy.   
 Even with the successful results of these findings, the studies researched had several 
limitations. Between all three trials, the population of participants who actually completed the 
entire study was low. The sample sizes 13, 19, and 254 respectively do not represent the 
generalized population. Another hindering aspect of the studies was that each study was 
conducted and measured differently.  While the Nelson study only looked at dextromethorphan 
and a placebo, the Sani study also used memantine and the active placebo, lorazepam, which 
may or may not have been the placebo used in the other two.  Finally, the third study, done by 
Shaibani, not only used a combo drug of dextromethorphan and quinidine, but also compared the 
results of different strengths of the dextromethorphan given.  A final limitation of all three 
studies was the lack of investigating the long-term effects of the drug on each patient.  As a 
cough suppressant, some adverse reactions seen with dextromethorphan include dizziness, 
fatigue, abdominal pain, nausea, and potential abuse. However, as a long term high-dose 
medication, other adverse reactions may be seen.  Changing a drug’s dosage and length of 
treatment warrants careful evaluation of the drug before prescribing it. None of the studies 
followed the patients long enough to record and track the effects of the drug long term.  The 
result of the studies is inclusive as an overview for the U.S. population due to several factors: the 
trials’ use of unlike controls (different drugs, drug combinations, and strength of drugs), the lack 
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of participants who completed all three studies, and the lack of investigation of long-term effects. 
Despite the limitations of these studies, hope for a new treatment for diabetic neuropathy still 
persists. 
CONCLUSION 
            Diabetic neuropathy is a common medical problem seen in diabetics.  Although 
numerous treatments are currently on the market for pain relief, many patients are still not seeing 
benefits from these medications.  Dextromethorphan has recently been tried as an alternative 
medication and has been proven to be a safe and effective for pain relief in patients with DN.  In 
the three randomly controlled, double blind clinical trials that were reviewed, it was found that 
dextromethorphan decreased the amount of pain experienced from the neuropathy more than that 
of the placebo.  Although these trials show positive results statistically in the use of 
dextromethorphan as a pain reliever, further studies must be done to warrant the appeal for the 
use in treating diabetics. Two main issues that should be addressed in future studies are the size 
of the study groups and long-term effects of the drug being investigated.  A larger research 
population will enable the results to give a better representation of the US population as well as a 
stronger validity to the results.  Examination of the long-term effects of this particular drug is 
important, as this drug was not originally manufactured for pain relief.  Detecting, knowing, and 
understanding all possible adverse reactions for any medication is very important, especially 
when it is being used to treat a chronic condition.  Even with the limitations presented, these 
three studies give hope for future treatments for the debilitating diabetic neuropathy.  
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